A Drug to Remember

The primary focus of ALZARROK is the development of a highly promising peptide drug, ALZ100, complemented by a superior delivery system, with the goal of halting the decline in cognitive function associated with Alzheimer’s disease. ALZARROK's patent-pending, multi-targeted peptide offers an efficient and synergistic approach to inhibit both neuroinflammation and neurodegeneration. This therapeutic peptide is being specifically designed for intranasal delivery, which is expected to provide two significant advantages over intravenous administration: first, it will enhance targeting efficiency and minimize degradation, and second, it will allow for convenient self-administration by patient.